Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study)
- PMID: 19920093
- DOI: 10.1093/rheumatology/kep354
Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study)
Abstract
Objective: To identify the determinants of anti-TNF-naive patients' preferences for the route of administration of anti-TNF agents.
Methods: The study was carried out in 50 Italian rheumatology centres (802 patients). All patients completed a 31-item questionnaire addressing their perceptions of current treatment and the preferences for treatment with anti-TNF agents. Statistical methods included analysis of variance (ANOVA), t-test and chi-square test.
Results: The response rate to the questionnaire was 97.6%. At the time of the survey, 310 (39.9%) patients were dissatisfied with current treatments, owing to inefficacy, side effects and inconvenience of administration. The i.v. and s.c. routes of administration were preferred by 50.2 and 49.8%, respectively. No significant difference was found in patients by gender, age, RA duration or number of drugs used. Reasons for the choice of i.v. administration were the safety of treatment at the hospital and the reassuring effect of physician presence. The s.c. administration was chosen for the convenience of treatment and in particular for home treatment. Patients dissatisfied with current therapy due to side effects preferred s.c. administration (P = 0.029), whereas patients choosing the i.v. route had slightly higher scores on 'today pain' (P = 0.047) and 'articular pain' (P = 0.023) of the Rheumatoid Arthritis Disease Activity Index (RADAI).
Conclusions: Both i.v. and s.c. treatments were well accepted by patients. However, treatment choice has to be discussed with patients, as individual preference seems to be determined by personal attitudes towards safety and convenience, by past experience and by the perception of current disease status.
Similar articles
-
Patient preferences for biologic agents in rheumatoid arthritis: a discrete-choice experiment.Value Health. 2013 Mar-Apr;16(2):385-93. doi: 10.1016/j.jval.2012.11.007. Value Health. 2013. PMID: 23538191
-
Patient preferences in choosing anti-TNF therapies-R1.Rheumatology (Oxford). 2006 Dec;45(12):1575-6. doi: 10.1093/rheumatology/kel369. Epub 2006 Nov 3. Rheumatology (Oxford). 2006. PMID: 17085468 No abstract available.
-
Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.Isr Med Assoc J. 2008 Apr;10(4):277-81. Isr Med Assoc J. 2008. PMID: 18548981 Clinical Trial.
-
Emerging biologic drugs for the treatment of rheumatoid arthritis.Autoimmun Rev. 2005 Nov;4(8):537-41. doi: 10.1016/j.autrev.2005.04.016. Autoimmun Rev. 2005. PMID: 16214092 Review.
-
Does route of administration affect the outcome of TNF antagonist therapy?Arthritis Res Ther. 2004;6 Suppl 2(Suppl 2):S19-23. doi: 10.1186/ar996. Epub 2004 Jun 21. Arthritis Res Ther. 2004. PMID: 15228617 Free PMC article. Review.
Cited by
-
Patient Preferences for Subcutaneous versus Intravenous Administration of Treatment for Chronic Immune System Disorders: A Systematic Review.Patient Prefer Adherence. 2021 Apr 19;15:811-834. doi: 10.2147/PPA.S303279. eCollection 2021. Patient Prefer Adherence. 2021. PMID: 33907384 Free PMC article. Review.
-
The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection.Patient Prefer Adherence. 2015 Jul 2;9:923-42. doi: 10.2147/PPA.S87271. eCollection 2015. Patient Prefer Adherence. 2015. PMID: 26170642 Free PMC article. Review.
-
Subcutaneous bortezomib for multiple myeloma treatment: patients' benefits.Patient Prefer Adherence. 2014 Jul 4;8:939-46. doi: 10.2147/PPA.S38142. eCollection 2014. Patient Prefer Adherence. 2014. PMID: 25045252 Free PMC article. Review.
-
Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic Review.Patient. 2014 Jul 12. doi: 10.1007/s40271-014-0075-y. Online ahead of print. Patient. 2014. PMID: 25015302
-
Openness to and preference for attributes of biologic therapy prior to initiation among patients with rheumatoid arthritis: patient and rheumatologist perspectives and implications for decision making.Patient Prefer Adherence. 2016 Jun 16;10:1079-90. doi: 10.2147/PPA.S107790. eCollection 2016. Patient Prefer Adherence. 2016. PMID: 27390518 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous